CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Generic Name||Pazopanib Hydrochloride|
|Indication||Soft Tissue Sarcoma (STS)|
|Funding Request||Adult patients with selective subtypes of advanced Soft Tissue Sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy. Funding is not requested for patients with GIST and adipocytic soft tissue sarcomas.|
|Pre Noc Submission||Yes|
|NOC Date||July 12, 2012|
|Submission Date||June 4, 2012|
|Submission Deemed Complete||June 11, 2012|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||June 18, 2012|
|Check-point meeting||July 24, 2012|
|pERC Meeting||September 20, 2012|
|Initial Recommendation Issued||October 4, 2012|
|Feedback Deadline ‡||October 19, 2012|
|pERC Reconsideration Meeting||November 15, 2012|
|Final Recommendation Issued||November 29, 2012|
|Notification to Implement Issued||December 14, 2012|
|Therapeutic Area||Soft Tissue Sarcoma|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.